Our team of experts guarantees the accuracy of each result, providing healthcare professionals with the support they need for clear and practical interpretation.

In addition, we provide ongoing advice and tools to optimize treatments and prevention, ensuring a more personalized approach.

Our commitment is to bring personalized genomic medicine to practical medical applications, convinced that effective integration of genomic studies allows for tailored treatments for each patient. In pharmacogenetics, this is key to significantly reducing side effects and optimizing treatments, offering truly personalized and efficient medical care.

In 2003, the decoding of the human genome marked a turning point in the history of medicine. It was also the moment that inspired the creation of Eugenomic, a company founded in 2009 with the firm conviction of bringing advances in genomic medicine and pharmacogenetics to clinical practice.

Since 2010, Eugenomic has established itself as an international leader, co-founded by Dr. Juan Sabater-Tobella, a renowned figure in the fields of biochemistry and pharmacogenetics, and his daughter, Ana Sabater Sales, a computer engineer. Their vision and experience have driven our commitment to transforming the way we understand and apply medicine, integrating genetic studies to optimize treatments, minimize risks, and enhance therapeutic efficacy.

As a result of this dedication, we also developed g-Nomic, one of the most advanced pharmacogenetic interpretation software programs in the world. A unique tool that helps healthcare professionals make personalized, evidence-based decisions.

At Eugenomic, we believe that genetics not only explains our past: it also shapes our future. And we work every day to ensure that future is synonymous with health, well-being, and precision medicine within everyone’s reach.

Dr. Juan Sabater – Tobella                    Link LinkedIn

Ana Sabater Sales                                    LinkedIn Link